946426-94-4

Basic information

• Product Name: 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole
• Synonyms: 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole
• CAS NO: 946426-94-4
• Molecular Weight: 347.038
• Mol File: 946426-94-4.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole(946426-94-4)
• EPA Substance Registry System: 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole(946426-94-4)

Safety Data

• Hazardous Substances Data: 946426-94-4(Hazardous Substances Data)

Upstream product

• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 447-61-0 2-Trifluoromethylbenzaldehyde 
• 74467-04-2 N-hydroxy-2-(trifluoromethyl)benzene-1-carbonimidoyl chloride 
• 74467-00-8 N-[[2-(trifluoromethyl)phenyl]methylidene]hydroxylamine 
• 1020569-65-6 ethyl 5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carboxylate 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 946426-88-6 5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-carboxylic acid methyl ester 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 946426-89-7 4-(hydroxymethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 

Downstream Products

• 1103500-20-4 TERN-101 
• 1103500-82-8 6-{4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]piperidin-1-yl}-1-methyl-1H-indole-3-carboxylic acid methyl ester 
• 1103501-11-6 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-((piperidin-4-yloxy)methyl)isoxazole 
• 1383739-71-6 2-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)benzo[d]thiazole-6-carboxylic acid 

Relevant articles and documents

PPARs-FXR multi-target micromolecular agonist as well as preparation method and application thereof

The invention discloses a PPARs-FXR multi-target micromolecule agonist and a preparation method and application thereof, the structure is shown in a general formula I, and the definition of each substituent group is shown in the description and claims. Th

Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio

The farnesoid X receptor (FXR) is a promising therapeutic target for nonalcoholic steatohepatitis (NASH) and other bile acid related diseases because it plays a critical role in fibrosis, inflammation and bile acid homeostasis. Obeticholic acid (OCA), a FXR agonist which was synthesized from chenodeoxycholic acid, showed desirable curative effects in clinical trials. However, the pruritus which was the main side effect of OCA limited its further applications in NASH. Although pruritus was also observed in the clinical trials of non-steroidal FXR agonists, the proportion of patients with pruritus was much smaller than that of OCA. Thus, we decided to develop non-steroidal FXR agonists and discovered a series of novel FXR agonists which were synthesized from GW4064 by replacing the stilbene group with ketoxime ether. Encouragingly, in the following biological tests, our target compounds 13j and 13z not only showed potent FXR agonistic activities in vitro, but also effectively promoted the expression of target genes in vivo. More importantly, in the pharmacokinetic experiments, compounds 13j and 13z displayed high liver/blood ratio characteristics which were helpful to reduce the potential side effects which were caused by prolonged systemic activation of FXR. In summary, our compounds were good choices for the development of non-steroidal FXR agonists and were deserved further investigation.

COMPOUNDS FOR MODULATING FXR

Provided herein are compounds of Formula (I), a stereoisomer, enantiomer or a pharmaceutically acceptable salt thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).